The FDA on September 22, 2021 approved JAKAFI® (Ruxolitinib) for chronic Graft-Versus-Host Disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. JAKAFI® is a product of Incyte Corp.
Bottom Ad
Advertisement
Subscribe
